Does UnitedHealthcare Cover Zepbound and Wegovy? Only If Your Employer Opted In

UnitedHealthcare covers Zepbound and Wegovy for weight loss only when your employer or plan has bought that coverage. UHC describes its weight-loss prior authorization as “an optional program” for clients that elect it, and its notice on the January 2027 drug list says most of its benefit plans leave weight-loss drugs out.^[1][4] An exclusion does not close every door. On plans that leave weight loss out, UHC runs separate programs: one pays for Zepbound when the diagnosis is sleep apnea, another for Wegovy when the goal is heart protection or treating MASH, each with strict medical-record requirements.^[2][3] People with type 2 diabetes can get Mounjaro or Ozempic through a separate diabetes review.^[7] UHC’s pharmacy benefit is run by Optum Rx, its sister company, so the drug lists and approval rules below are the ones Optum Rx applies.

Two different ways UHC can pay for these drugs

Which row you are in is a question for your employer, not for UHC’s clinicians. Self-funded employers decide the benefit themselves, and fully insured plans follow what the employer bought plus any state rules. UHC’s October 2026 bulletin added a separate weight-loss program for regulatory requirements in California, New Mexico, New York and North Dakota, so plans in those states may follow state rules on top of the employer’s choice.^[5] Our employer coverage checker lists the questions to put to HR.

If your plan covers weight-loss drugs

UHC’s weight-loss criteria, effective October 1, 2026, are shorter than many insurers’. They ask for:

• Age. Older than 16 for Zepbound; 12 or older for Wegovy injection.^[1]
• Lifestyle changes alongside the drug, such as a reduced-calorie diet, exercise, behavioral support or a community program. UHC does not name a minimum number of months before the drug starts, where Aetna asks for six.^[1]
• A BMI of 30 and up, or 27 and up alongside abnormal cholesterol, hypertension, type 2 diabetes, sleep apnea or another illness linked to weight.^[1]

The first approval runs five months for Wegovy and six months for Zepbound. To renew for 12 months, you need to have lost at least 5% of your starting weight while continuing the lifestyle changes. An August 2026 change helps people who titrate slowly: if you have been on the drug six months or less and have not yet reached a maintenance dose, UHC grants one more six-month approval to get there.^[1] Optum Rx also limits fills to four pens per 28 days for both drugs.^[6]

UHC says the Wegovy pill is “typically excluded” even on plans that cover weight-loss drugs, and its Advantage drug list will exclude the tablets outright from January 1, 2027, naming Wegovy injection and Zepbound among the alternatives.^[1][4] Our Wegovy pill cost guide covers the self-pay price for anyone set on the tablet.

If your plan excludes weight loss: Zepbound for sleep apnea

The FDA cleared Zepbound for obstructive sleep apnea, at moderate or severe levels, in people who also have obesity.^[9] In the two SURMOUNT‑OSA trials, the number of breathing interruptions per hour of sleep fell by 25 to 29 events on tirzepatide against about 5 on placebo over a year.^[11] UHC’s sleep apnea program, effective September 1, 2026, exists for members whose plan excludes weight-loss drugs, and its bar is higher than the weight-loss route.^[2] The prescriber has to submit records showing:

• Age 18 or older, with a BMI of 30 and up.
• A sleep study showing more than 15 breathing events an hour.
• At least one earlier diet attempt that did not work.
• Continuing symptoms despite using CPAP or another positive airway pressure device for at least four hours a night on 70% of nights, or a reason you cannot use one.
• No diabetes and an A1C no higher than 6.5%. People with diabetes are expected to use the diabetes drugs instead.
• No planned surgery for sleep apnea or obesity, counseling on sleep position and on avoiding alcohol or sedatives at bedtime, and a prescriber who is a sleep specialist, lung or ear-nose-throat doctor, or experienced in treating sleep apnea.

Approval lasts six months. To renew, someone not using CPAP needs a follow-up sleep study showing fewer events than at the start, and after a year on the drug, at least a 50% drop. Someone still on CPAP needs to have lost at least 10% of body weight instead.^[2] Plan the follow-up sleep study before the first approval runs out. Our article on Zepbound for sleep apnea covers the trials in more depth.

Plans without weight-loss coverage: Wegovy after a heart attack or stroke, or for MASH

Two of Wegovy’s FDA approvals have nothing to do with the scale. One is for people who already have cardiovascular disease and carry extra weight, to make a heart attack, stroke or heart-related death less likely; the other is for MASH with stage F2 or F3 liver scarring.^[10] UHC’s program for plans that exclude weight loss, effective May 1, 2026, covers both uses.^[3]

For heart-risk reduction UHC is narrower than the label. The patient must be at least 45, have a BMI 27 and up, and have records of a past heart attack, a past stroke, or peripheral artery disease that causes symptoms, and must already be taking the standard drugs for that condition, such as a statin, an antiplatelet and a blood-pressure drug, unless they cannot. Diabetes, an A1C above 6.5% or the most severe class of heart failure rules a patient out. Approval runs 12 months, and renewal needs only continued diet and activity changes.^[3] For MASH, the fibrosis stage has to be documented, for example by a FibroScan liver stiffness test. Our article on GLP‑1 drugs and fatty liver explains the condition.

Mounjaro and Ozempic for type 2 diabetes

UHC’s diabetes program, effective July 1, 2026, covers Mounjaro and Ozempic, along with Rybelsus and Trulicity, once the prescriber sends chart notes confirming type 2 diabetes: an A1C of 6.5% or more, a qualifying fasting or glucose tolerance result, or, for someone diagnosed more than two years ago, records of the diagnosis. Approval runs 12 months. The same document says these drugs are not approved for weight loss and that weight-loss use is “typically excluded.”^[7] Optum Rx caps Ozempic at one pen and Mounjaro at four pens per 28 days.^[6]

UnitedHealthcare Medicare members

For UHC Medicare members, weight-loss coverage comes from outside the plan. Since July 1, 2026, the federal Medicare GLP‑1 Bridge has paid for three products used for weight management (Foundayo, Wegovy in pen or tablet form, and the Zepbound KwikPen), run by Medicare with its own prior authorization rather than through the member’s Part D plan. UHC’s notice to prescribers stresses that the single-dose Zepbound pen and Zepbound vials are not included, and neither are Ozempic or Mounjaro.^[8] Our Medicare GLP‑1 Bridge guide covers who qualifies and what it costs.

If UHC says no

1. Find out which program reviewed the request. A denial under the weight-loss program on a plan that excludes the category cannot be won on appeal. A request under the sleep apnea or heart-risk program is a clinical review, and missing records are the usual reason it fails.
2. Check the sleep study and the CPAP log. For the sleep apnea route, most of what UHC asks for comes from the sleep clinic. Ask for the device’s usage report, which shows whether you met the four-hours-a-night standard.
3. Appeal on the clock. Our guide to prior authorization and appeals covers the federal deadlines.
4. Ask HR about next year. Employers revisit the weight-loss benefit at renewal.

Paying cash works with any plan. Lilly sells the Zepbound KwikPen and vial from $299 a month, with doses from 7.5 mg at $449 when refilled on time, and Novo Nordisk sells Wegovy pens for $349 a month at most doses and the pill from $149.^[12][13] Our list of the cheapest GLP‑1 options without insurance compares them with every other route.